Bibliografía
[1]
Segovia J, Bermejo J, Alfonso F. Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (New Orleans, Estados Unidos, 24-27 de marzo de 2007). Rev Esp Cardiol. 2007; 60:626-38..
,
[2]
Bermejo J, Segovia J, Alfonso F. Resumen de los ensayos clínicos presentados en las Sesiones Científicas anuales de la American Heart Association 2007 (Orlando, Estados Unidos, 4-7 de noviembre de 2007). Rev Esp Cardiol. 2008; 61:185-93..
,
[3]
Segovia J, Bermejo J, Alfonso F. Resúmenes de los ensayos clínicos presentados en la 57. Sesión Científica Anual del American College of Cardiology (Chicago, Estados Unidos, 30 de marzo-2 de abril de 2008). Rev Esp Cardiol. 2008; 61:726-37..
,
[4]
Bermejo J, Segovia J, Alfonso F. Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (New Orleans, Estados Unidos, 8-12 de noviembre de 2008). Rev Esp Cardiol. 2009; 62:178-87..
,
[5]
Segovia J, Bermejo J, Alfonso F. Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Orlando, Estados Unidos, 28-31 de marzo de 2009). Rev Esp Cardiol. 2009; 62:660-9..
,
[6]
Heras M, Bermejo J, Segovia J, Alfonso F. Resumen de los ensayos clínicos presentados en las sesiones científicas del Congreso de la Sociedad Europea de Cardiología (Barcelona, España, 29 de agosto-2 de septiembre de 2009). Rev Esp Cardiol. 2009; 62:1149-60..
,
[7]
Pé rez de Isla L, Bayes-Genis A, Sanchis J, Heras M. Resumen de los ensayos clí nicos presentados en las Sesiones Cientí ficas Anuales de la American Heart Association (Orlando, Estados Unidos, 14-18 de noviembre de 2009). Rev Esp Cardiol. 2010; 63:190-9..
,
[8]
Pé rez de Isla L, Bayes-Genis A, Sanchis J, Heras M. Resumen de los ensayos clí nicos presentados en las Sesiones Cientí ficas Anuales del American College of Cardiology (Atlanta, Estados Unidos, 14-16 de marzo de 2010). Rev Esp Cardiol. 2010; 63:695-707..
,
[9]
Bayes-Genis A, Avanzas P, Pé rez de Isla L, Sanchis J, Heras M. Resumen de estudios clí nicos presentados en el Congreso de 2010 de la European Society of Cardiology [28(] de agosto-1 de septiembre de 2010, Estocolmo, Suecia). Rev Esp Cardiol. 2010; 63:1292-303..
,
[10]
Tang SLA, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al; for the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010 Nov 14 [Epub ahead of print]. doi: 10.1056/NEJMoa1009540..
,
[11]
Zannad F, McMurray JVJ, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H, et al; for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2010 November 14 [Epub ahead of print]. doi: 10.1056/NEJMoa1009492..
,
[12]
Aaronson KD, Slaughter MS, McGee E, Cotts WG, Acker MA, Jessup ML. Evaluation of the HeartWare® HVAD left ventricular assist device system for the treatment of advanced heart failure: results of the ADVANCE bridge to transplant trial. Circ Re s. 2 010 Novembe r 12 [Epub ahead of p r i n t]. d o i: 10.1161 /RES.0b013e3182014899..
,
[13]
Hernandez AF, O’Connor CM, Starling RC, Armstrong PW, Dickstein K, Gennivois D. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Circ Res. 2010 November 12 [Epub ahead of print]. doi: 10.1161/RES.0b013e3182014899..
,
[14]
Ellenbogen KA, Gold MR, Meyer TE, Fernández Lozano I, Mittal S, Waggoner AD, et al. Primary results from the SmartDelay Determined AV Optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: A randomized trial comparing empirical echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 November 15 [Epub ahead of print]. doi: 10.1161/CIRCULATIONAHA.110.992552..
,
[15]
Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al, for the DEFINE Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 November 17 [Epub ahead of print]. doi: 10.1056/NEJMoa1009744..
,
[16]
Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P. ASCOT: The Anglo- Scandinavian Cardiac Outcomes Trial (ASCOT): Testing C-reactive protein at baseline and on-treatment as an independent predictor of cardiovascular outcomes. Circulation. 2010; 122:2219 [citado Nov 2010]. Disponible en: http://sciencenews. myamericanheart.org/pdfs/Abstract_ASCOT.pdf..
,
[17]
Nicholls SJ, Ballantyne CM, Kastelein JJ, Taylor AJ, Gordon A, Johansson J, et al. Results of the First Major Clinical Trial of An Oral Agent Inducing Apo A1 Synthesis: A New Approach to HDL Raising and CV Risk Modification. Circulation. 2010; 122:2220..
,
[18]
Patel MR; for ROCKET AF Executive Steering Committee. Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation (ROCKET AF) Circulation. 2010; 122:2217..
,
[19]
Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation. JAMA. 2010:1;304:2363-72..
,
[20]
Furlan A, Massaro J, Mauri L, Adams H, Albers G, Felberg R, et al. CLOSURE I: A prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the STARFlex® septal closure system versus best medical therapy in patients with a stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Circulation. 2010; 122:2218..
,
[21]
Price MJ. Standard versus high-dose clopidogrel according to platelet function testing after PCI: Results of the GRAVITAS Trial. Circulation. 2010; 122:2218..
,
[22]
Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, for the BASKET-PROVE Study Group. Late cardiac death and myocardial infarction associated with late stent thrombosis in large vessel stenting after 1st or 2nd generation drug-eluting compared to bare-metal stents: the BASKET PROspective Evaluation Examination. N Engl J Med. [2010] November 16 [Epub ahead of print]. doi: 10.1056/NEJMoa1009406..
,
[23]
Esler M. Symplicity HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Lancet. 2010 November 17 [Epub ahead of print]. doi: 10.1016/S0140-6736(10)62039-9..
,
[24]
Hiatt WR, Baumgartner II, Nikol S, Van Belle E, Driver VR, Norgren L. NV1FGF gene therapy on amputation-free survival in critical limb ischemia—Phase 3 randomized double-blind placebo-controlled trial (TAMARIS). Circulation. 2010; 122:21..
,
[25]
Berwanger O, ACT Investigators. ACT: Acetylcystein for the Prevention of Contrast- Induced nephropaThy (ACT) Trial: a pragmatic multicenter randomized trial to evaluate the efficacy of acetylcysteine for the prevention of renal outcomes in patients undergoing coronary and vascular angiography. Circulation. 2010; 122:2219..
,